The present invention relates to a method useful for forming products which are useful in a pharmaceutical context and products formed by such a method. The invention is a solvent-free method of forming a metastable polymorph of a pharmaceutical active ingredient the method comprising the steps of: placing an amorphous or crystalline compound into an extruder; providing a source of heat to the extruder to heat the compound to a temperature in the range of from 8 °C below the melting point of th...

A combination comprising 2 to 8 mg of 5-[4-[2-(N-methyl-N- (2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-24-dione (rosiglitazone) or a tautomeric form thereof or a pharmaceutically acceptable salt or solvate thereof; and sub maximal amount of sulphonylurea selected from glibenclamide glipizide gliclazide tolazamide tolbutamide acetohexamide carbutamide chlorpropamide glibornuride gliquidone glisentide glisolamide glisoxepide glyclopyamide and glycylamide. Disclosed is also a medical use of the co...

PURPOSE: A combination kit containing pinitol and a drug for preventing or treating diabetes is provided to reduce side effects and to quickly treat diabetes. CONSTITUTION: A combination kit of a component for preventing or treating diabetes contains pinitol as a first ingredient and a drug of biguanide meglitinide or sulfonylurea as a second ingredient. The biguanide is metformin. The meglitinide is repaplinide or nateglinide. The sulfonylurea is carbutamide acetohexamide chlorpropamide tolbuta...

595024 Disclosed herein is a compound which is NN-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbomoyl-4-yloxy)pyrimidine-2-carboxamide a pharmaceutical composition comprising it and a pharmaceutical composition further comprising an anti-obesity agent and an anti-diabetic agent. Wherein said anti-obesity agent is selected from the group consisting of dirlotapide mitratapide implitapide lorcaserin cetilistat PYY3-36 naltrexone oleoyl-estrone obinepitide pramlintide tesofensine leptin liraglut...

A polymeric construct is disclosed. The construct comprises a polysaccharide polymer having a selected medicament associated therewith. The medicament th us present is provided in a slow release form. lt;SDOCL LA=ENgt; 18 We Claim 1. A polymeric construct comprising a polysaccharide polymer having a selected medicament entrapped therewithin. 2. The construct as defined in claim 1 wherein said polymer is selected from the group consisting of alginic acid or a pharmaceutically acceptable salt ther...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2...